在1型糖尿病临床免疫疗法试验中监测小岛特异性免疫反应
Sefina Arif1, Clara Domingo-Vila1, Emily Pollock1
1Department of Immunobiology, King's College London, London, United Kingdom.
Frontiers in immunology
|June 7, 2023
概括
强大的免疫监测测定对于1型糖尿病 (T1D) 临床试验至关重要. 这些测定检测到岛屿特异性T细胞,作为指导治疗和分层免疫治疗干预患者的生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 生物标志物发现发现
背景情况:
- 扩大针对1型糖尿病 (T1D) 的免疫治疗临床试验需要先进的免疫监测工具.
- 岛屿特异性T细胞是指导T1D药物选择,剂量和疗效评估的重要生物标志物.
- 生物标志物有助于患者分层进行临床试验适宜性和基准测试.
研究的目的:
- 审查目前的免疫监测技术,以检测和表征T1D中小岛特异性免疫反应.
- 探索多聚合物,抗原诱导标记测定和单细胞转录概况的整合.
- 突出这些联合技术在理解T1D免疫干预机制方面的潜力.
主要方法:
- 审查常用的免疫监测测定,包括多重和抗原诱导标记测定.
- 讨论将这些分析与单细胞转录概况分析结合起来.
- 强调从单个样本获得的多参数数据,以发现和验证生物标志物.
主要成果:
- 岛屿特异性T细胞可以作为T1D免疫疗法中的预测生物标志物.
- 结合测试提供了更深入的洞察力免疫干预机制相比抗原不可知的方法.
- 技术进步通过多参数数据促进了协调的生物标志物发现和验证.
结论:
- 免疫监测试验的协调对于可靠的T1D生物标志物发现至关重要.
- 先进的技术为治疗对T1D病变发生的影响提供了独特的见解.
- 多参数数据分析是推进T1D免疫治疗策略和患者护理的关键.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Insulin: Dosing Regimen and Adverse Effects
216
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
216
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K


